Drug Profile
Research programme: human genomics - CHUQ/SignalGene
Alternative Names: Breast cancer research programme - SignalGene/CHUQ; human genomics research programme - SignalGene/CHUQ; Osteoporosis research programme - Signal Gene/CHUQLatest Information Update: 02 Dec 2002
Price :
$50
*
At a glance
- Originator Centre Hospitalier Universitaire de Quebec; SignalGene [CEASED]
- Developer Centre Hospitalier Universitaire de Quebec
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Osteoporosis; Psoriasis
Most Recent Events
- 15 May 2002 Discontinued - Preclinical for Breast cancer in Canada (unspecified route)
- 15 May 2002 Discontinued - Preclinical for Osteoporosis in Canada (unspecified route)
- 09 May 2002 Discontinued - Preclinical for Psoriasis in Canada (unspecified route)